Paramune focuses on novel molecular mechanisms to treat cancers and autoimmune diseases more effectively. Our targets arise from transformative new insights into disease pathology. We employ a variety of next-generation biologic formats including monoclonal antibodies, bispecifics, engagers and antibody cocktails to make possible the most favorable activity and safety profiles. Our approaches target disease mechanisms at the fundamental level, and as a result have the potential to achieve superior results as compared to current therapeutic approaches.
Member count: 1-10
Founded date: 2020
Investors 1
| Date | Name | Website |
| 23.04.2021 | MBC BioLab... | mbcbiolabs... |